The Argus II, a “bionic eye”, is intended to provide electrical stimulation of the retina to elicit visual perception in blind subjects with severe to profound retinitis pigmentosa, according to the ...

SYLMAR, Calif.--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are ...

Argus II is a novel healthcare technology that restores vision in RP patients. Improvements in visual acuity are expected to lead to improvements in patient self-confidence, decreasing their ...

This undated product image provided by Second Sight Medical Products shows a new implantable device that takes the place of damaged cells inside the eye. The Food and Drug Administration on Thursday, ...

A new final guidance document published by the US Food and Drug Administration (FDA) recommends to sponsors methods of conducting clinical research in support of investigational medical device ...

SYLMAR, Calif.--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are ...

University Hospitals Eye Institute in Cleveland has announced that it will begin offering patients the Argus II Retinal Prosthesis System, a “bionic eye” designed to treat late stage retinitis ...

Last year, Wentai Liu watched as surgeons implanted a microchip he had designed into the eye of a blind patient. For Liu, a professor of electrical engineering in the Baskin School of Engineering at ...

A project at Shanghai's Fudan University has developed a new retinal prosthesis and used it to restore vision to a number of blind mice. Described in Science the implant is said to offer advantages ...

Argus II Retinal Prosthesis fitted patients incurred a discounted incremental cost of 42,455 Euros in comparison to the patient given 'CAU' over the 25 years of time. Progressive improvement in the ...